TITLE

Prolonged Duration of Response to Infliximab in Early But Not Late Pediatric Crohn's Disease

AUTHOR(S)
Kugathasan, Subra; Werlin, Steven L.; Martinez, Alfonzo; Rivera, Maria T.; Heikenen, Janice B.; Binion, David G.
PUB. DATE
November 2000
SOURCE
American Journal of Gastroenterology;Nov2000, Vol. 95 Issue 11, p3189
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVES: Tumor necrosis factor-α plays a central role in chronic intestinal inflammation of Crohn's disease. Targeting this cytokine with the chimeric monoclonal antibody infliximab has emerged as an effective form of therapy in adult Crohn's disease patients. We sought to determine whether infliximab treatment would benefit pediatric patients with medically refractory Crohn's disease. We also assessed the duration of response, comparing children with early disease to children with long-standing (late) Crohn's disease. METHODS: Fifteen consecutive children (mean age 12.8 ± 3.2 yr) with medically refractory Crohn's disease were enrolled in a prospective, open-label trial of a single, 5-mg/kg infliximab intravenous infusion. Medically refractory disease was defined as an inability to taper steroids, lack of response to immunomodulator therapy over 4 months, and active disease as measured by the Pediatric Crohn's Disease Activity Index (PCDAI). Primary endpoints included measurements of disease activity (PCDAI), steroid use, and duration of clinical response. RESULTS: In all, 14/15 children (94%) improved after infliximab infusion, with a significant decrease of both PCDAI and daily steroid use by 4 wk. Ten patients (67%) achieved complete remission by 10 wk. Among the 14 patients who responded, three of six children (50%) with early disease maintained clinical response through the 12-month trial period, compared to none of eight children with late disease. There were no serious complications associated with the use of infliximab in any of the patients. CONCLUSIONS: Infliximab is safe and effective in the short-term treatment of medically refractory pediatric Crohn's disease. More importantly, there is a remarkably prolonged duration of response after infliximab therapy in children with early compared to late Crohn's disease.
ACCESSION #
17628587

 

Related Articles

  • Treatment of Crohn Disease with Anti--Tumor Necrosis Factor Agent.  // Annals of Internal Medicine;6/19/2007, Vol. 146 Issue 12, pI20 

    The article examines the effectiveness regarding the use of anti-tumor necrosis factor agent in treating patients with Crohn's disease. A chronic inflammatory bowel disease, the symptoms of Crohn' disease include diarrhea, fever and abdominal pain. Key information about the methods and results...

  • BIOLOGICS IN INFLAMMATORY BOWEL DISEASE: HOW MUCH PROGRESS HAVE WE MADE? Sandborn, W. J.; Faubion, W. A. // Gut;Sep2004, Vol. 53 Issue 9, p1366 

    The article focuses on the progress made in the treatment of inflammatory bowel disease with biologic therapies, concentrating primarily on the tumor necrosis factor (TNF) inhibitors infliximab, etanercept, adalirnumab, CDP87O, CDP571 and onercept, and on the selective adhesion molecule...

  • Association study of TNFSF15 polymorphisms in Japanese patients with inflammatory bowel disease. Kakuta, Y.; Kinouchi, Y.; Negoro, K.; Takahashi, S.; Shimosegawa, T. // Gut;Oct2006, Vol. 55 Issue 10, p1527 

    The article presents a letter entitled "Association study of TNFSF 15 polymorphisms in Japanese patients with inflammatory bowel disease," by Y. Kakuta, Y. Kinouchi and K. Negoro published within the issue. The study focuses on the role of tumor necrosis factor superfamily 15 in patients with...

  • Management of Latent Tuberculosis during TNF Antagonist Administration.  // Clinical Infectious Diseases;9/15/2005, Vol. 41 Issue 6, preceding p1 

    The article cites a research study on management of Latent Tuberculosis during (Tumor Necrosis Factor) TNF Antagonist Administration. It informs that patients who receive TNF antagonists for treatment of rheumatologic or inflammatory bowel disease are at significantly increased risk of...

  • Certolizumab pegol: Pegylated TNF-alpha blocker for Crohn's disease. Tanzi, Maria G. // Pharmacy Today;Jun2008, Vol. 14 Issue 6, p18 

    The article reports on the approval of the first and only pegylated tumor necrosis factor (TNF)-alpha blocker in the U.S. The medication was approved in April 2008. It is used in the treatment of Crohn's disease and for maintaining clinical response in adult patients with moderate to severe...

  • Maintenance of Remission in Crohn’s Disease: Current and Emerging Therapeutic Options. Brookes, Matthew J.; Green, Jonathon R.B. // Drugs;2004, Vol. 64 Issue 10, p1069 

    Crohn's disease is a chronic inflammatory bowel disorder with a relapsing and remitting course. Once remission is achieved, the main aim of the management of Crohn's disease is maintenance of that remission. Significant advances have been made into understanding the aetiology and pathogenesis of...

  • Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease. Gisbert, Javier P; Chaparro, María // American Journal of Gastroenterology;Sep2013, Vol. 108 Issue 9, p1426 

    OBJECTIVES:Anti-tumor necrosis factor (TNF) drugs are an effective therapeutic option in patients with inflammatory bowel disease (IBD). However, data regarding their safety during pregnancy and breastfeeding are scarce. The aim of this study was to critically review available data on the safety...

  • The classics in perspective. Panés, Julián; Ghosh, Subrata // Gut;Sep2007, Vol. 56 Issue 9, p1184 

    The authors reflect on the development of anti-cytokine therapies as biological agents in treating Crohn's disease and inflammatory diseases. Their therapeutic approach to these diseases has expanded. They noted that gastroenterologists face a remarkable wave of new biological therapies for...

  • TNFα inhibitor induced lupus-like syndrome (TAILS) in a patient with IBD. LUPU, A.; TIERANU, C.; CONSTANTINESCU, C. L.; DICULESCU, M. // Current Health Sciences Journal;2014, Vol. 40 Issue 4, p285 

    Background: In patients with autoimmune diseases like inflammatory bowel diseases there has been reported a drug-induced lupus like syndrome secondary to TNFα inhibitors. Objective: clinical case presentation and literature review of patients who develop lupus-like syndrome in relation to...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics